SEP 2·SEC EDGARLow
Bianchi Francesco sold $132K of LIVN
Bianchi Francesco sold 1,650 shares of LivaNova PLC (LIVN) at $79.72 ($0.13M total) on 2026-08-31.
StockNASDAQ · US · USDHealthcare · Medical Devices
$LIVN
LivaNova PLC
alphai earnings readSecond-quarter 2026 · AUG 5LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS GuidanceVerdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $LIVNvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 0
- Bearish
- 1
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.0M 3 txs
Tezel Ahmet2× · $877K
10b5-1 share of filings0%
Top stories · $LIVNMore →
AUG 31·stocktitan.net
LivaNova (NASDAQ: LIVN) officer to sell 1,650 shares
LivaNova PLC (LIVN) officer Francesco Bianchi plans to sell 1,650 shares of common stock under Rule 144, valued at $131,538. The shares stem from vested restricted stock units awarded in 2023 and 2024. Bianchi also sold 1,800 shares in May 2026 and 1,200 shares in June 2026.
AUG 13·SEC EDGAR
Tezel Ahmet sold $208K of LIVN
Tezel Ahmet (Chief Innovation Officer) sold 2,675 shares of LivaNova PLC (LIVN) at $77.74 ($0.21M total) on 2026-08-11.
LIVN sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning LIVN (LivaNova PLC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent LIVN coverage spans earnings, insider activity and financial news.
In the last 30 days, LIVN insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.0M). The most active reporter was Tezel Ahmet, Chief Innovation Officer, with 2 filings.
What's driving LIVN
A modest insider sale by a director may signal limited confidence but the amount is small relative to market cap.
The insider sale introduces modest additional float, likely exerting slight downward pressure on LIVN.
This is an insider open-market sale, not a 10b5-1 plan, which can modestly affect near-term sentiment but is not a fundamental catalyst by itself.
This is a routine insider sale to the issuer, not a new operating or financial catalyst.
Guidance upgrade supports earnings and revenue expectations, but the free cash flow cut and higher capex raise near-term cash-flow risk.
alphai scores every news story that mentions LIVN with an AI model for sentiment and relevance, and aggregates insider trades from LivaNova PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $LIVN
Score
Bianchi Francesco sold $132K of LIVN
Bianchi Francesco sold 1,650 shares of LivaNova PLC (LIVN) at $79.72 ($0.13M total) on 2026-08-31.
1 min readLivaNova (NASDAQ: LIVN) officer to sell 1,650 shares
LivaNova PLC (LIVN) officer Francesco Bianchi plans to sell 1,650 shares of common stock under Rule 144, valued at $131,538. The shares stem from vested restricted stock units awarded in 2023 and 2024. Bianchi also sold 1,800 shares in May 2026 and 1,200 shares in June 2026.
1 min readTezel Ahmet sold $208K of LIVN
Tezel Ahmet (Chief Innovation Officer) sold 2,675 shares of LivaNova PLC (LIVN) at $77.74 ($0.21M total) on 2026-08-11.
1 min readTezel Ahmet sold (to issuer) $669K of LIVN
Tezel Ahmet (Chief Innovation Officer) sold (to issuer) 8,589 shares of LivaNova PLC (LIVN) at $77.86 ($0.67M total) on 2026-08-11.
2 min read
LivaNova (LIVN) Q2 2026 Earnings Call Transcript
LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.
6 min readLivaNova PLC Q2 2026 Earnings Call Summary
LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.
7 min readLivaNova Q2 Earnings Call Highlights
LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.
6 min readLivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.
7 min readWhy is LivaNova stock climbing today?
LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.
3 min readLivaNova PLC (LIVN): Results of Operations and Financial Condition
LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8% – Raised full-year 2026 revenue and adj
6 min read